AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34757189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation continued
Number of subjects: 1795
Study 34757189 — intervention group
Group type: EXPERIMENTAL
Intervention: No anticoagulation
Number of subjects: 1795
Study 34757189 — intervention group
Group type: COMPARATOR
Intervention: Any anticoagulation strategy
Number of subjects: 1795
Study 34757194 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-oHSV2
Number of subjects: 0
Study 34757194 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-oHSV2-stimulated NK92 cells with anti-NKG2A and anti-HLA-E treatment
Number of subjects: 0
Study 34757489 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC-OX (oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy)
Number of subjects: 20
Study 34757602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone tablets
Number of subjects: 288
Study 34757602 — intervention group
Group type: COMPARATOR
Intervention: Pirfenidone capsules
Number of subjects: 288
Study 34757602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (tablets and substitution)
Number of subjects: 288
Study 34757602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (overall)
Number of subjects: 288
Study 34757829 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced obesity treatment
Number of subjects: 0
Study 34757973 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence measured electronically in a subcohort of 324 clients.
Number of subjects: 14632
Study 34757973 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of running out of ART after national lockdown.
Number of subjects: 14632
Study 34757973 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression in HIV clients.
Number of subjects: 14632
Study 34758807 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) using a novel blood glucose monitoring (BGM) system
Number of subjects: 359
Study 34758808 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise training
Number of subjects: 0
Study 34758808 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity continuous exercise training
Number of subjects: 0
Study 34758857 — intervention group
Group type: COMPARATOR
Intervention: Ankle exoskeleton during inclined walking
Number of subjects: 11
Study 34758857 — intervention group
Group type: COMPARATOR
Intervention: Ankle exoskeleton for stair climbing
Number of subjects: 11
Study 34758857 — intervention group
Group type: EXPERIMENTAL
Intervention: Device usability metrics for CP cohort
Number of subjects: 11
Study 34758857 — intervention group
Group type: EXPERIMENTAL
Intervention: Device usability metrics for unimpaired cohort
Number of subjects: 11
Study 34758857 — intervention group
Group type: EXPERIMENTAL
Intervention: System Usability Scale score for exoskeleton
Number of subjects: 11
Study 34758861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature thoracoscopic-laparoscopic oesophagectomy
Number of subjects: 214
Study 34758861 — intervention group
Group type: COMPARATOR
Intervention: Open oesophagectomy
Number of subjects: 214
Study 34758861 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic-laparoscopic oesophagectomy
Number of subjects: 214
Study 34758881 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth platform for electronic PRO collection
Number of subjects: 101
Study 34758995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 0.6 µg/kg in 10 min followed by continuous infusion at 0.4 µg/kg/hour until dural closure)
Number of subjects: 0
Study 34758995 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (identical volume to dexmedetomidine group)
Number of subjects: 0
Study 34758995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 34758995 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 34759712 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index (BMI)
Number of subjects: 768
Study 34759712 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 768
Study 34754421 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of postoperative vital signs abnormalities
Number of subjects: 0
Study 34754421 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of postoperative vital signs
Number of subjects: 0
Study 34760950 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Care
Number of subjects: 0
Study 34760950 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study 34760951 — intervention group
Group type: EXPERIMENTAL
Intervention: External Counterpulsation
Number of subjects: 0
Study 34760951 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34761160 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urine collection
Number of subjects: 153
Study 34761160 — intervention group
Group type: COMPARATOR
Intervention: 24-hour estimated excretion from spot urine sample
Number of subjects: 153
Study 34761160 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced biomarker models
Number of subjects: 153
Study 34761647 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA tubes
Number of subjects: 3568
Study 34761647 — intervention group
Group type: COMPARATOR
Intervention: Streck tubes
Number of subjects: 3568
Study 34761647 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at -80 °C
Number of subjects: 3568
Study 34761647 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 3568
Study 34761647 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisomy 21
Number of subjects: 3568
Study 34761647 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 3568
Study 34761647 — intervention group
Group type: EXPERIMENTAL
Intervention: Male fetus
Number of subjects: 3568
Study 34761647 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisomy 18
Number of subjects: 3568
Study 34761647 — intervention group
Group type: EXPERIMENTAL
Intervention: Turners syndrome
Number of subjects: 3568
Study 34761647 — intervention group
Group type: EXPERIMENTAL
Intervention: Triploidy
Number of subjects: 3568
Study 34761665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 180
Study 34761665 — intervention group
Group type: COMPARATOR
Intervention: Rotational atherectomy (RA)
Number of subjects: 180
Study 34761878 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy (pembrolizumab combined with chemotherapy)
Number of subjects: 1
Study 34762062 — intervention group
Group type: EXPERIMENTAL
Intervention: Global COVID-19 Registry Database
Number of subjects: 64114
Study 34762062 — intervention group
Group type: EXPERIMENTAL
Intervention: Agile project management approach
Number of subjects: 64114
Study 34762062 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection from 306 sites
Number of subjects: 64114
Study 34762093 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA and arsenic trioxide regimen (chemotherapy-free) for standard-risk APL
Number of subjects: 154
Study 34762093 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA and arsenic trioxide regimen with 4 doses of idarubicin during induction therapy for high-risk APL
Number of subjects: 154
Study 34762093 — intervention group
Group type: COMPARATOR
Intervention: Historical control group from AAML0631 study
Number of subjects: 154
Study 34762513 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 34762513 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with aortic stenosis and mitral valve insufficiency
Number of subjects: 0
Study 34762658 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenomas
Number of subjects: 767
Study 34762658 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenomas larger than 2 cm
Number of subjects: 767
Study 34762658 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided adenomas
Number of subjects: 767
Study 34762658 — intervention group
Group type: COMPARATOR
Intervention: Serrated lesions
Number of subjects: 767
Study 34762776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysosmia
Number of subjects: 60
Study 34762776 — intervention group
Group type: COMPARATOR
Intervention: Normosmia
Number of subjects: 60
Study 34762863 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless pregnancy monitor
Number of subjects: 118
Study 34762863 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless pregnancy monitor and intrauterine pressure catheter
Number of subjects: 118
Study 34762863 — intervention group
Group type: COMPARATOR
Intervention: Tocodynamometry
Number of subjects: 118
Study 34763085 — intervention group
Group type: EXPERIMENTAL
Intervention: eladocagene exuparvovec
Number of subjects: 26
Study 34763195 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily
Number of subjects: 22
Study 34763234 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence group
Number of subjects: 0
Study 34763234 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishing exercise habits
Number of subjects: 0
Study 34763234 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulting a physical therapist during hospitalization
Number of subjects: 0
Study 34763665 — intervention group
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol (DCI) 600 mg, two times per day for 30 days
Number of subjects: 10
Study 34763665 — intervention group
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol (DCI)
Number of subjects: 10
Study 34763776 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular imaging with phosphatidylserine microbubbles (MB)
Number of subjects: 17
Study 34763776 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 or 0.15 mL of MB
Number of subjects: 17
Study 34763939 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective LLL assessment based on limb volume change (LVC) using circumferential limb measurements
Number of subjects: 150
Study 34764171 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia and transversus thoracis muscle plane block (TTPB)
Number of subjects: 42
Study 34764171 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia only
Number of subjects: 42
Study 34764171 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia and TTPB
Number of subjects: 42
Study 34764932 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine
Number of subjects: 0
Study 34764932 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34764938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass index (FMI)
Number of subjects: 0
Study 34764938 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 0
Study 34764938 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 0
Study 34765102 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG247 Smart Heart Sensor
Number of subjects: 150
Study 34765102 — intervention group
Group type: COMPARATOR
Intervention: Holter monitor
Number of subjects: 150
Study 34765108 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + Bevacizumab (B)
Number of subjects: 0
Study 34765108 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 0
Study 34765307 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 2 weeks until disease progression or unacceptable toxicity
Number of subjects: 6
Study 34765319 — intervention group
Group type: EXPERIMENTAL
Intervention: mAdAPT-001 (AdAPT-001) injected intratumorally
Number of subjects: 50
Study 34765319 — intervention group
Group type: EXPERIMENTAL
Intervention: mAdAPT-001 (AdAPT-001) injected intravenously
Number of subjects: 50
Study 34765593 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-Based Constraint-Induced Therapy Program
Number of subjects: 0
Study 34765593 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34766208 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy, viscous placebo breakfast (PLA)
Number of subjects: 14
Study 34766208 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-food breakfast (FOOD)
Number of subjects: 14
Study 34766208 — intervention group
Group type: COMPARATOR
Intervention: Water-only breakfast (WAT)
Number of subjects: 14
Study 34766217 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin-based chemotherapy (including regimens other than BR)
Number of subjects: 40
Study 34766217 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin-based chemotherapy
Number of subjects: 40
Study 34766217 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin-based chemotherapy with subsequent hematopoietic stem cell transplantation (HSCT)
Number of subjects: 40
Study 34766330 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (inpatient setting)
Number of subjects: 5351
Study 34766330 — intervention group
Group type: COMPARATOR
Intervention: Supported discharge and multidisciplinary home rehabilitation
Number of subjects: 5351
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vaccination rates for hepatitis A virus (HAV)
Number of subjects: 287
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vaccination rates for hepatitis B virus (HBV)
Number of subjects: 287
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vaccination rates for seasonal influenza
Number of subjects: 287
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vaccination rates for pneumococcus
Number of subjects: 287
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of vaccination recommendations
Number of subjects: 287
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative IgG anti-HAV antibody status
Number of subjects: 287
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative IgG HBV surface antibody status
Number of subjects: 287
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with newspaper subscription
Number of subjects: 287
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with physician recommendation for vaccination
Number of subjects: 287
Study 34766576 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with use of anti-tumor necrosis factor agents
Number of subjects: 287
Study 34767089 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation services
Number of subjects: 7
Study 34767131 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 173
Study 34767652 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim at 5 μg/kg in morbidly obese patients
Number of subjects: 30
Study 34767652 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim at 5 μg/kg in non-obese patients
Number of subjects: 30
Study 34767652 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim dosing based on actual body weight
Number of subjects: 30
Study 34767753 — intervention group
Group type: EXPERIMENTAL
Intervention: CRKP infection in China (n=246)
Number of subjects: 991
Study 34767753 — intervention group
Group type: EXPERIMENTAL
Intervention: CRKP infection in South America (n=109)
Number of subjects: 991
Study 34767753 — intervention group
Group type: EXPERIMENTAL
Intervention: CRKP infection in the USA (n=130)
Number of subjects: 991
Study 34767753 — intervention group
Group type: COMPARATOR
Intervention: CRKP infection in China
Number of subjects: 991
Study 34767753 — intervention group
Group type: COMPARATOR
Intervention: CRKP infection in the USA
Number of subjects: 991
Study 34767753 — intervention group
Group type: COMPARATOR
Intervention: CRKP infection in South America
Number of subjects: 991
Study 34767753 — intervention group
Group type: COMPARATOR
Intervention: CRKP infection in South America vs China
Number of subjects: 991
Study 34767753 — intervention group
Group type: COMPARATOR
Intervention: CRKP infection in USA vs China
Number of subjects: 991
Study 34767753 — intervention group
Group type: COMPARATOR
Intervention: CRKP infection in USA vs South America
Number of subjects: 991
Study 34767759 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine (100 μg in 0.5 mL intramuscularly, 2 doses, 28 days apart)
Number of subjects: 791
Study 34767765 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine (HPV4) or nonavalent HPV vaccine (HPV9) administered in three doses over 6 months (on day 1, at month 2, and at month 6).
Number of subjects: 453
Study 34767765 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV9 in female participants aged 16-26 years
Number of subjects: 453
Study 34767765 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV4 in male participants aged 16-26 years
Number of subjects: 453
Study 34767765 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV9 in female participants aged 9-15 years
Number of subjects: 453
Study 34767765 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV4 in female participants aged 9-15 years
Number of subjects: 453
Study 34767765 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV4 in male participants aged 9-15 years
Number of subjects: 453
Study 34767785 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermidine (Spd) supplementation
Number of subjects: 0
Study 34767785 — intervention group
Group type: COMPARATOR
Intervention: Loss of SMOX
Number of subjects: 0
Study 34767825 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 3 s (FEV3)
Number of subjects: 832
Study 34767825 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 6 s (FEV6)
Number of subjects: 832
Study 34767985 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic ICD lead monitoring alerts
Number of subjects: 4942
Study 34767985 — intervention group
Group type: COMPARATOR
Intervention: Pacing impedance threshold alert
Number of subjects: 4942
Study 34767985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead monitoring alerts
Number of subjects: 4942
Study 34768160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 570
Study 34768160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic Obesity (SO)
Number of subjects: 570
Study 34768160 — intervention group
Group type: COMPARATOR
Intervention: Obesity
Number of subjects: 570
Study 34768160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Nutritional Assessment (MNA) as a mediator
Number of subjects: 570
Study 34768176 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 89
Study 34768176 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 89
Study 34768176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 89
Study 34768176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose protocol with prolonged infusion
Number of subjects: 89
Study 34768178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (FFA)
Number of subjects: 732
Study 34768178 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (Control)
Number of subjects: 732
Study 34768339 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute encephalopathy group (10 patients)
Number of subjects: 30
Study 34768339 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 30
Study 34768516 — intervention group
Group type: EXPERIMENTAL
Intervention: OviTex (reinforced tissue matrix)
Number of subjects: 92
Study 34768571 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14++CD16+ monocytes in peripheral blood (PB)
Number of subjects: 66
Study 34768692 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BFT) performed once or twice a week during the temporary stoma period
Number of subjects: 44
Study 34768692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback therapy)
Number of subjects: 44
Study 34769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosive reflux disease (ERD)
Number of subjects: 58
Study 34769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilic esophagitis (EoE)
Number of subjects: 58
Study 34769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Schatzki ring (SR)
Number of subjects: 58
Study 34769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal esophagus
Number of subjects: 58
Study 34769657 — intervention group
Group type: EXPERIMENTAL
Intervention: ERD and SR with UES insufficiency
Number of subjects: 58
Study 34769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal motility disorders
Number of subjects: 58
Study 34769680 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Medical Home (PCMH)
Number of subjects: 22
Study 34769680 — intervention group
Group type: EXPERIMENTAL
Intervention: Change strategies employed to implement PCMH innovations
Number of subjects: 22
Study 34771451 — intervention group
Group type: EXPERIMENTAL
Intervention: APVO436
Number of subjects: 4
Study 34771728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine plus bevacizumab
Number of subjects: 0
Study 34772318 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics strategies used for 8 weeks; frequency of use >50% for 5 days a week.
Number of subjects: 0
Study 34772318 — intervention group
Group type: COMPARATOR
Intervention: Participatory ergonomics strategies; no specific control group mentioned.
Number of subjects: 0
Study 34772347 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting Nano plus stent
Number of subjects: 2481
Study 34772362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid valve surgery (TV group)
Number of subjects: 48
Study 34772362 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery (MV group)
Number of subjects: 48
Study 34772362 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TV and MV groups
Number of subjects: 48
Study 34772417 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of thin-cap fibroatheroma (TCFA) in culprit lesions
Number of subjects: 434
Study 34772417 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual syntax score (rSS) divided into three groups
Number of subjects: 434
Study 34772417 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 434